Abstract: The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM.

Abstract: The present invention relates to pharmaceutical compositions comprising a unit dose of at least 1 mg of an antibody to oncostatin M (OSM) and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition comprises an antibody that blocks OSM from interacting with OSM receptor gp130.

Abstract: The present invention relates to receptor/reporter fusion protein based assays for detecting an effect test compounds have on a particular membrane receptor, as well as to receptor/reporter fusion proteins for use in such assays and compounds identified by the assays as having interesting/useful effects. Suitable membrane receptors are growth factor receptors, cytokine receptors, ion channels and integrins including any subtypes, mutants, homologs and chimeric forms of such receptors. The assay is particularly suited to studying G-protein coupled receptors (GPCRs).

Abstract: The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory arthropathy or inflammatory disorder, and the use of OSM in screening for such antagonists.